|Bid||7.58 x 3000|
|Ask||7.61 x 1300|
|Day's range||7.07 - 7.62|
|52-week range||1.55 - 19.39|
|Beta (5Y monthly)||2.87|
|PE ratio (TTM)||N/A|
|Earnings date||11 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||25.50|
Salicyn 30 is an antiviral that blocks infection of cells by the novel coronavirus. COVIDTRAP is an ACE2 receptor decoy, which could bind up the coronavirus and keep it from infecting cells. Brian Orelli: You've got a couple of other treatments that you're working on.
Ji thinks the company's neutralizing antibodies are potentially more active than the frontrunners, which could help the biotech catch up and compete. Brian Orelli: We talked about a lot of different products. Henry Ji: Brian, our company has a lot of expertise, especially the antibodies space.
While multiple vaccines have completed phase 3 clinical trials or will in the coming months, Sorrento's lead vaccine, T-VIVA-19, hasn't even entered clinical trials yet. Brian Orelli: You do have a vaccine that you're working on called T-VIVA-19.